Needham Reiterates Hold on Neurocrine Biosciences
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Neurocrine Biosciences (NASDAQ:NBIX).

August 29, 2024 | 9:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Neurocrine Biosciences, indicating a neutral stance on the stock.
The reiteration of a Hold rating by Needham suggests that the analyst sees no immediate catalysts for significant price movement in either direction. This neutral stance implies that investors should neither expect a strong upward nor downward movement in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100